BeOne Medicines (ONC) Capital Expenditures (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Capital Expenditures data on file, last reported at $43.2 million in Q1 2026.

• Quarterly Capital Expenditures fell 27.93% year-over-year to $43.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $169.1 million (up 744.01% YoY) and the FY2025 annual result came in at $185.8 million, up 164.3% from the prior year.
• Capital Expenditures slipped to $43.2 million in Q1 2026 per ONC's latest filing, from $133.8 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $454.3 million in Q4 2023 and bottomed at -$329.9 million in Q4 2024.
• The 5-year median for Capital Expenditures is $60.0 million (2025), against an average of $62.3 million.
• Peak annual rise in Capital Expenditures reached 274.33% in 2023, while the deepest fall reached 228.34% in 2023.
• Tracing ONC's Capital Expenditures over 5 years: stood at $121.4 million in 2022, then surged by 274.33% to $454.3 million in 2023, then tumbled by 172.61% to -$329.9 million in 2024, then soared by 140.56% to $133.8 million in 2025, then plunged by 67.67% to $43.2 million in 2026.
• Per Business Quant, the three latest ONC Capital Expenditures figures stand at $43.2 million (Q1 2026), $133.8 million (Q4 2025), and -$5.9 million (Q3 2025).

Peer Comparison